{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li B"],"funding":["NCI NIH HHS"],"pagination":["e45"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5379017"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(3)"],"pubmed_abstract":["<h4>Background</h4>One approach to identify patients who meet specific eligibility criteria for target-based clinical trials is to use patient and tumor registries to prescreen patient populations.<h4>Objective</h4>Here we demonstrate that the Total Cancer Care (TCC) Protocol, an ongoing, observational study, may provide a solution for rapidly identifying patients with CD30-positive tumors eligible for CD30-targeted therapies such as brentuximab vedotin.<h4>Methods</h4>The TCC patient gene expression profiling database was retrospectively screened for CD30 gene expression determined using HuRSTA-2a520709 Affymetrix arrays (GPL15048). Banked tumor tissue samples were used to determine CD30 protein expression by semiquantitative immunohistochemistry. Statistical comparisons of Z- and H-score"],"journal":["JMIR research protocols"],"pubmed_title":["Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility."],"pmcid":["PMC5379017"],"funding_grant_id":["P30 CA076292"],"pubmed_authors":["Trepicchio WL","Fenstermacher D","Eschrich SA","Mitchell M","Dalton WS","Li B","Berglund A","Danaee H","Dai H","Sullivan D"],"additional_accession":[]},"is_claimable":false,"name":"Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.","description":"<h4>Background</h4>One approach to identify patients who meet specific eligibility criteria for target-based clinical trials is to use patient and tumor registries to prescreen patient populations.<h4>Objective</h4>Here we demonstrate that the Total Cancer Care (TCC) Protocol, an ongoing, observational study, may provide a solution for rapidly identifying patients with CD30-positive tumors eligible for CD30-targeted therapies such as brentuximab vedotin.<h4>Methods</h4>The TCC patient gene expression profiling database was retrospectively screened for CD30 gene expression determined using HuRSTA-2a520709 Affymetrix arrays (GPL15048). Banked tumor tissue samples were used to determine CD30 protein expression by semiquantitative immunohistochemistry. Statistical comparisons of Z- and H-score","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Mar","modification":"2025-04-26T04:56:46.979Z","creation":"2019-03-27T02:40:16Z"},"accession":"S-EPMC5379017","cross_references":{"pubmed":["28320689"],"doi":["10.2196/resprot.7289"]}}